Related Experiment Video

Updated: Jul 19, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf

N Nakai1, T Kishida, M Shin-Ya

  • 1Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Gene Therapy
|October 7, 2006
PubMed

Insights

Microphthalmia-associated transcription factor (Mitf) is crucial for melanoma cell survival. Mitf-specific siRNA effectively reduced melanoma tumor growth and induced apoptosis, suggesting a potential RNAi therapy for malignant melanoma.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Microphthalmia-associated transcription factor (Mitf) is vital for melanocytic cell differentiation and melanin synthesis.
  • Previous research on Mitf's role in melanoma cell survival is conflicting.
  • Investigating Mitf's essentiality in melanoma is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of Mitf in melanoma cell survival.
  • To evaluate the therapeutic potential of Mitf-specific siRNA in a melanoma model.
  • To assess the efficacy of RNA interference (RNAi) therapy against malignant melanoma.

Main Methods:

  • Synthesized and utilized Mitf-specific short interfering RNA (siRNA) duplexes.
  • Performed in vitro lipid-mediated siRNA transfection in B16 melanoma cells.
  • Administered siRNA via intratumoral electroporation in a mouse model of subcutaneous melanoma.

Main Results:

  • Mitf-specific siRNA significantly downregulated Mitf and its target tyrosinase in vitro.
  • siRNA treatment led to a remarkable reduction in melanoma cell viability through apoptosis induction.
  • In vivo, Mitf-specific siRNA drastically inhibited subcutaneous melanoma outgrowth, unlike non-specific siRNA.
  • Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling confirmed apoptosis in Mitf-siRNA treated tumors.

Conclusions:

  • Mitf plays a significant role in the survival of melanoma cells.
  • Intratumoral electrotransfer of Mitf-specific siRNA represents a promising therapeutic strategy for malignant melanoma.
  • RNAi targeting Mitf offers a potential new avenue for melanoma treatment.

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...